RotaShield Data On Intussusception May Be Ready By October
Executive Summary
Wyeth-Ayerst may have additional information on the relationship between RotaShield and intussusception from a multi-state case control study in time for the next CDC Advisory Committee on Immunization Practices meeting in October.
You may also be interested in...
CDC To Review Intussusception Cases With Vaccines Other Than RotaShield
The Centers for Disease Control & Prevention is conducting a retrospective review to determine whether intussusception is associated with vaccines other than Wyeth-Ayerst's RotaShield.
CDC To Review Intussusception Cases With Vaccines Other Than RotaShield
The Centers for Disease Control & Prevention is conducting a retrospective review to determine whether intussusception is associated with vaccines other than Wyeth-Ayerst's RotaShield.
American Home Products
Second quarter earnings reflect a $53 mil. charge against earnings for the estimated costs associated with the suspension of RotaShield rotavirus vaccine shipments (1"The Pink Sheet" July 19, p. 4). Worldwide net sales decreased 1% to $398.7 mil. for the second quarter based on the RotaShield charge and decreased agricultural and animal product sales, the company stated. Net income was $398.7 mil., down 24%. Pharmaceutical sales were up 8% for the second quarter to $2.24 bil., based on Effexor XR, Enbrel, Zosyn, Ziac, and generic product sales increases